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Abstract
Background—Heart failure (HF) is a chronic disease that compromises patients’ quality of life 
(QoL). Interventions designed to reduce distress and improve disease self-management are needed. 
We evaluated the efficacy of a telephone-based coping skills training (CST) intervention.
Methods and Results—This randomized clinical trial involved 180 HF outpatients with 
reduced ejection fraction. Participants ranged in age from 29 to 87 years (mean = 58 years); 27% 
were women and 47% were non-Caucasian. Participants were randomized to either a CST 
intervention or heart failure education (HFE), both delivered over 16 weeks. The primary 
outcomes were: (i) post-intervention effects on QoL and HF disease biomarkers (both with 
alpha=0.01), and; (ii) a composite measure of time to death or first hospitalization (with 
alpha=0.03) over a median follow-up period of 3 years. CST resulted in greater improvements in 
QoL compared to HFE (P<.01), including the Kansas City Cardiomyopathy Questionnaire 
(KCCQ)(P=.009), depressive symptoms (P=.027), and the six-minute walk test (P=.012). 
However, it did not differentially improve HF disease biomarkers, or reduce risk of all-cause 
hospitalizations or death (HR = 0.84 [0.59, 1.12]). Interestingly, exploratory analyses showed that 
participants randomized to CST experienced a reduction in the composite endpoint of worsening 
HF hospitalization or death during the 3-year follow-up period (HR = 0.65 [0.44, 0.98], P = .040).
Conclusions—CST improved QoL in patients with HF. Monitoring and improving QoL is 
emerging as an important aspect of the clinical management of HF that can reduce disease burden 
and may help improve clinical outcomes in this vulnerable patient population.
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Introduction
An estimated 5.7 million American adults are living with heart failure (HF), and another 
870,000 new cases are diagnosed each year.1 HF is the most costly diagnosis in the 
Medicare population and is the most common cause for hospitalization in patients over the 
age of 65 years. Although medical management helps control symptoms and stabilizes 
patients, HF is nonetheless an inherently unstable condition, with frequent hospitalizations 
being one manifestation of this instability. The associated annual direct and indirect costs for 
HF patient care in the United States are estimated to be in excess of $39 billion.1,2
HF is a chronic condition with broad-ranging impact, affecting almost every important 
aspect of patients’ lives. Consequently, psychological distress is prevalent in patients with 
HF and quality of life (QoL) is often markedly impaired. Major depressive disorder is a 
common manifestation of the difficulties in coping with distress experienced by patients 
with HF.3 Impaired QOL and elevated depressive symptoms are associated with an adverse 
HF disease trajectory and poor clinical outcomes.4, 5
Traditional behavioral interventions designed to help HF patients remain in stable health and 
avoid preventable hospital admissions have focused on patient education, diet and 
medication adherence, and physical activity.6 Overall, the evidence supporting these disease 
management strategies has been mixed, but some have resulted in prolonged event-free 
survival, decreased the number of hospital admissions and improved QoL.7, 8 Although the 
most effective interventions have involved regular home visits by a nurse, telephone-based 
interventions also have been found to be effective, and because they are more convenient for 
patients and relatively inexpensive compared to face-to-face encounters, there is a need to 
further develop and refine these approaches.9
Coping effectively with chronic disease can require significant behavioral change. Coping 
skills training (CST) is a cognitive-behavioral approach to disease self-management that 
transforms maladaptive coping styles into more constructive behaviors, facilitates 
compliance with medical treatment recommendations, and improves psychological well-
being.10 CST has been shown to both enhance self-management and improve patient health 
and QoL in a number of chronic diseases, including diabetes and pulmonary disease.10, 11 
However, the CST approach to disease management has not been studied widely in patients 
with HF.12 Because HF is a chronic disease that requires rigorous medical self-management, 
health behavior change, and psychological adjustment, a CST intervention focused on both 
disease self-management and alleviating psychological distress has the potential to be of 
significant value for HF patients.
The objective of this trial was to evaluate the efficacy of a CST intervention, delivered over 
the telephone to HF patients, on three outcomes: post-intervention QoL, HF disease 
biomarkers, and longer term clinical outcomes defined by hospitalization or death. In order 
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to achieve equipoise, a heart failure education (HFE) intervention was selected as the control 
condition.
Methods
Trial Overview
COPE-HF was a single-site randomized clinical trial in which 180 men and women with HF 
were randomized to either CST or HFE. Participants were enrolled between September 2009 
and January 2014. Details of the study design, assessments and interventions were published 
previously.13
Participants
The study sample consisted of 180 men and women with documented HF. Patients were 
recruited from the HF Programs at Duke University Medical Center, the UNC Health Care 
system, and the Durham VA Medical Center. The protocol was approved by the respective 
institutional review boards at these centers and written informed consent was provided by 
each participant. Inclusion criteria were: men or women aged 18 or older; New York Heart 
Association (NYHA) Class II-III HF of at least 3-months duration; and left ventricular 
ejection fraction (LVEF) ≤ 40% documented within 6 months of study enrollment. Exclusion 
criteria were: myocardial infarction or coronary artery revascularization within 3 months of 
enrollment; HF due to a correctable cause or condition, such as uncorrected primary valvular 
disease; alcohol or drug abuse within 12 months; illnesses such as malignancies that are 
associated with a life-expectancy of <12 months; current pregnancy; and inability to provide 
informed consent.
Stratification and Randomization
Participants were randomized in a 1:1 ratio to either CST or HFE. A conditional 
randomization procedure (PROC PLAN in SAS 9.2) was used to stratify participants 
according to etiology of HF (ischemic versus non-ischemic) and age (<60 years versus ≥ 60 
years). To maintain allocation concealment, group assignments were placed in sealed 
envelopes and opened sequentially at the time of randomization.
Outcome Measures
The primary outcomes were: (i) post-intervention effects on QoL and HF disease biomarkers 
and; (ii) a composite measure of time to either all-cause death or hospitalization. The 
primary measure of HF disease biomarkers was a global score of B-type Natriuretic Peptide 
(BNP)14, LVEF15, 24-hour heart rate variability (HRV) indexed by the standard deviation of 
normal R-R intervals (SDNN)16, flow mediated dilation of the brachial artery (FMD)17, and 
plasma C-reactive protein (CRP).18 The primary QoL index was a global score of the Kansas 
City Cardiomyopathy Questionnaire (KCCQ)19, Beck Depression Inventory II (BDI-II)20, 
Speilberger State-Trait Anxiety Inventory (STAI)21, HF Attitudes About Impairment (AAI) 
questionnaire22 and the 6-minute walk test (6MWT). Hospitalizations were categorized as 
“all-cause”‘, “cardiovascular’’ and “HF” (worsening HF) based upon medical records. Death 
was verified from hospital and EMS records.
Sherwood et al. Page 3
Circ Heart Fail. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Secondary outcomes were the components of the HF disease and QoL global score 
measures. Health behaviors important for HF self-management were assessed prior to 
randomization and immediately upon completion of the intervention. Routine daily physical 
activity was assessed using an accelerometer (Actiwatch®-64, Mini Mitter Co., Inc., Bend, 
Oregon) worn on the wrist of the non-dominant arm for 24-hours. Medication adherence was 
assessed using the Medication Event Monitoring System (or MEMS®) bottle cap in–home 
for 10 days. Dietary sodium intake was estimated from a 24-hour standardized dietary recall 
with a nutritionist, as well as by 24-hour urinary sodium excretion. In addition, we 
administered an established questionnaire that was designed to assess self-care in HF 
patients, defined by a combination of maintenance, symptom perception and management 
behaviors.23 Post-treatment assessments were performed within 2 weeks after completing 
the intervention. All outcome assessments were performed by research team members 
blinded to group assignment.
Interventions
Coping Skills Training (CST)—CST was delivered by a clinical psychologist (B.M.H.), 
and was comprised of 16 weekly 30-minute individual phone calls. Cognitive behavioral 
techniques were patterned after previous studies involving pulmonary11, 24 and cardiac25 
patients. Motivational interviewing was utilized to enhance adherence to prescribed health 
behaviors. All CST participants received the same set of topics. For the initial 4 sessions 
involving health behaviors (diet and salt restriction, daily weighing, physical activity, 
medication adherence), participants could prioritize the order in which each health behavior 
was covered. The remaining 12 sessions were presented in the same sequence and including 
specific coping techniques (relaxation training, cognitive restructuring, visualization, 
problem solving, and activity pacing). Two optional modules addressing depression and 
assertiveness training were incorporated into the intervention at the discretion of the 
interventionist based upon patient needs.
Heart Failure Education (HFE)—The HFE intervention was delivered by a Physician’s 
Assistant (PA) and also involved 16 weekly individual phone calls of up to 30-minutes 
duration, providing a control for weekly patient contact, but focused upon the provision and 
discussion of medical issues important for HF self-management without teaching behavioral 
skills to improve coping. The interventionist (J.S.) provided information regarding HF health 
behaviors, including symptom monitoring, importance of daily weighing, adherence to 
medications, physical activity, and optimal diet.
All study participants continued with their regular medical care, including their routine 
cardiology visits and management of any episodes of escalating symptoms or disease 
progression.
Statistical Analysis
All analyses were performed with SAS 9.3 (Cary, NC), and the evaluation of all intervention 
effects were based on the principle of intention-to-treat, with missing post-treatment data 
managed using multiple imputation within PROC MI, using 100 imputations. The effects of 
treatment on the QoL and HF disease severity variables were assessed using two separate 
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general linear models in which a rank-based global score of all QoL and HF disease markers 
served as the respective outcome variable, as suggested by O’Brien26 for the examination of 
multiple endpoints.27 This general analytic approach has previously been utilized in multiple 
cardiac trials and is recommended for examining multiple, related outcome variables within 
a domain of interest simultaneously.28 Consistent with this ‘gatekeeper’ methodology, if a 
global score analysis showed evidence of a treatment group difference, we conducted 
subsequent analyses examining the individual outcomes in a secondary, explanatory step.
Evaluation of treatment effects on clinical outcomes used separate Cox proportional hazards 
models (PHREG). These analyses addressed all-cause first hospitalization or death as 
primary and cardiovascular hospitalization or death as supportive. Additional supportive 
analyses addressed worsening HF hospitalization or death, and death. For these analyses, the 
time of event was the index date, and participants with no dates were censored at the time of 
last contact with study staff or documentation in their medical record. All proportional 
hazards models controlled for age, HF etiology, baseline BNP, LVEF, and number of 
hospitalizations within the past year. We also examined the impact of treatment on HF 
hospitalization and death using the Wei-Lin-Weissfeld (WLW) method, which allows deaths 
after HF hospitalization to be taken into account.29 This approach has been advocated for 
use among patients with chronic diseases due to the multiple natures of most “hard” clinical 
events in these populations, which are often clustered within individuals.30
An additional set of proportional hazards analyses were conducted in which changes in QoL 
served as the predictor of interest. Within this model, time to first HF hospitalization or 
death, and time to death, using the WLW approach served as the outcome with change in 
QoL (post-treatment residualized for pre-treatment) as the predictor of interest and baseline 
QoL, BNP, LVEF, age, etiology of HF, and number of hospitalizations within the past year 
as control variables. Only events occurring after post-treatment assessments were considered 
in these models. These exploratory analyses also examined individual QoL indices.
Power Calculation
With respect to the global HF severity and QoL scores, we estimated power assuming an 
attrition rate of about 20% and multiple imputation for missing data. We identified a 
standardized effect size of about a half-standard deviation as clinically meaningful for the 
HF biomarker and QoL global scores.31 For testing a given global index at 0.01, so as to 
account for multiple comparisons, approximately100 patients in each treatment arm, 
provides about .90 power to detect a standardized effect size of 0.60.
Power for the Cox regression model was estimated assuming an event rate of 70% in the 
control group, 42 months for patient accrual, a median follow-up time of 3 years and a 
minimum follow-up time of 15 months. With approximately 100 patients in each group, we 
estimated power of about 0.90 to detect a hazard ratio of 0.50 by a two-sided test at 0.05. For 
testing at 0.03, to account for multiple comparisons, the power is .90 to detect a hazard ratio 
of 0.47.
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Results
Participant Flow
Figure 1 displays the flow of participants during the trial. Of 584 men and women referred 
for potential participation, 199 were consented, 190 completed pre-treatment assessments, 
and 180 were randomized. One participant randomized to CST died prior receiving any 
treatment and was excluded in the analysis. The intent-to-treat (ITT) analyses were therefore 
based on a study sample of 179 participants.
Participant Characteristics
Demographic, clinical, and baseline characteristics are presented in Table 1. Although 
treatment groups were comparable on most background characteristics, the HFE group 
tended to have a higher percentage of participants with implantable cardiac defibrillators 
(ICDs) at baseline, as well as lower LVEF.
Treatment Adherence
Treatment adherence during the study intervention was excellent, with 95% of participants 
completing post-intervention assessments. Average duration of the weekly telephone 
intervention calls were 10 minutes for HFE and 26 minutes for CST. Among individuals in 
the CST group, participants were present for an average of 14.5 (SD = 3.5) sessions and 
80% of these participants attended 14 or more sessions. Among individuals in the HFE 
group, participants were present for an average of 15.7 (SD = 1.6) sessions and 90% of 
individuals participated in all 16 sessions. Post-treatment data were available on all but 9 
patients (8 in the CST group and 1 in the HFE group). Among the 9 patients with missing 
post-treatment assessments, 7 discontinued their randomly assigned intervention prior to its 
completion (6 in the CST group and 1 in the HFE group). Among the other 2 patients in the 
CST group with missing post-treatment assessments, 1 died prior to completion of the CST 
intervention and 1 completed the CST intervention but did not participate in the post-
treatment assessment. In relation to the three year follow up of clinical outcomes, there was 
0% attrition.
Primary Outcomes
Quality of Life—Examination of post-intervention changes in QoL demonstrated that the 
CST group exhibited significantly greater improvements in the QoL global score compared 
with HFE (P <.01) (Table 2). Of the QoL component measures, the CST group exhibited 
greater improvements the KCCQ and 6MWT distance, and a greater reduction in depressive 
symptoms measured by the BDI-II compared to HFE. The remaining QoL components (AAI 
and STAI) showed trends toward greater improvements in the CST group. Follow-up 
analyses of changes in depressive symptoms also revealed a baseline depression by 
treatment group interaction (P = .001), such that individuals exhibiting clinically elevated 
symptoms at baseline (BDI≥ 14; n = 77 [37 in HFE, 40 in CST]) showed reductions in 
depressive symptoms that were greater among individuals in CST (8.3 [1.4, 5.6]) relative to 
HFE (3.8 [1.4, 6.5]) (P = .023).
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HF Biomarkers—Although HF biomarkers showed improvement over time (data not 
shown), post-treatment comparisons for HF disease biomarkers revealed no significant 
differences between CST and HFE (P = .114) (Table 2).
Follow-up Clinical Events—Over a median 3 years of follow-up (range 0.2 to 5.7 years), 
127 participants experienced at least one criterion clinical event (all-cause hospitalization or 
death), 106 experienced at least one cardiac event (MI, stroke, cardiac revascularization, or 
death), and 80 experienced at least one HF hospitalization (n = 65) or died (n = 15). In this 
latter set of analyses, 24 participants whose first event was a HF hospitalization 
subsequently died. As shown in Table 3, compared to HFE, the CST intervention exhibited 
trends towards reduced risk of first all-cause hospitalization or death (HR = 0.84 [0.59, 
1.12], P>.03) and first cardiovascular hospitalization or death (HR = 0.78 [0.53, 1.16], P >.
03). CST participants were more clearly less likely to experience a worsening HF 
hospitalization or die during follow-up (HR = 0.63 [0.40, 1.01], P = .055); this effect 
appeared to be driven by the CST group tending to have a lower mortality rate (HR = 0.53 
[0.27, 1.06], P = .072). Follow-up analyses, integrating both of the latter models using the 
Wei-Lin-Weissfeld (WLW) method, demonstrated that the CST group was less likely to 
experience a worsening HF hospitalization or die during follow-up (HR = 0.65 [0.44, 0.98], 
P = .040), with 3-year worsening HF hospitalization or death rates of 37% for the CST 
group and 50% for the HFE group (Table 3; Figure 2). Mortality rates in the CST group 
were nearly 50% less than that observed in HFE, with a 3-year mortality rate of only 8% in 
the CST group compared to 15% in the HFE group.
Secondary Outcomes
Health Behaviors and HF Self-Management—All participants showed post-
intervention improvements in HF self-management scores: HF management (mean increase 
8.6 [6.7, 10.5], P = .024), HF maintenance (mean increase 7.6 [6.3, 8.8], P = .036), and HF 
self-care (mean increase = 10.4 [9.0, 11.7], P < .001), as well as reduced urinary sodium 
excretion (mean reduction 339 [126, 552], P = .028) and increased physical activity levels 
(mean increase in arbitrary actigraphy units 18252 [5814, 30690], P = .005). However, there 
were no significant intervention group differences in these improvements, nor were there 
treatment group differences in medication adherence.
Association between QOL Improvements and Clinical Outcomes—Post-
intervention improvements on our global score measure of QoL were associated with a 
reduced likelihood of HF hospitalization or death (P = .001). Examination of individual QoL 
components revealed that greater improvements in the KCCQ (P = .007), 6MWD (P = .012), 
AII (P = .045) and STAI (P = 0.05) were most strongly associated with reduced clinical 
events, whereas the BDI-II (P = .088) showed a somewhat weaker association.
Discussion
The COPE-HF randomized clinical trial demonstrated that a coping skills training (CST) 
intervention resulted in marked and broad-ranging improvements in QoL for patients with 
HF. Among the most notable improvements were health-related QoL, assessed by the 
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KCCQ, which increased by an average of over 8 points in patients randomized to CST, 
reflecting a significant improvement in patients’ clinical status.32 Functional capacity 
assessed by the 6-minute walk test also increased by over 15 meters in the CST group, 
which is indicative of the favorable clinical changes produced by the CST intervention.32 By 
comparison, the HF-ACTION trial reported that 3-months of aerobic exercise training also 
resulted in a similar 15 meter increase in the 6-minute walk test, but a more modest increase 
in the KCCQ of less than 2 points, compared with usual care.33, 34 Depressive symptoms, 
assessed by the BDI-II were reduced by over 4 points in participants randomized to CST, 
and other measures of psychological well-being also showed favorable trends towards 
improvement compared to the HFE control group. Importantly, post-intervention QoL was 
associated with improved event-free survival. These findings underscore the perspective that 
QoL in HF patients should be considered an important treatment target.
Although participants in the CST intervention showed no greater improvement in HF disease 
biomarkers compared to patients randomized to the education control condition, there was 
some indication that it lowered the risk of death or hospitalization for worsening HF over an 
average follow-up period of 3 years. The CST intervention was not associated with reduced 
all-cause hospitalizations or mortality, but participants in the CST group did show a notable 
35% reduction in risk of HF hospitalization or death compared to HFE participants. 
Importantly, the improved survival benefits found for the CST intervention are compared to 
a HF education control intervention that itself is also likely to have had a favorable impact 
on event-free survival, as patient education and the non-specific effects of attention and 
support have been shown to be beneficial.6 Moreover, the CST intervention involved weekly 
phone calls for 16 weeks, but its benefits persisted years after its completion, suggesting that 
the skills and techniques mastered during the intervention were retained over the course of 
the follow up period.
Because health behaviors that are relevant to HF self-management are important to HF 
outcomes, we examined the impact of treatment on important HF health behaviors. Our 
measures of dietary sodium intake indicated that a post-intervention reduction was evident in 
both CST and HFE groups. Medication adherence was generally high in all participants and 
did not improve further as a result of the interventions, while self-reported HF self-
management behaviors improved in both intervention groups. Therefore, while both 
treatment groups demonstrated improvements in health behaviors, such improvements do 
not account for the greater benefits of CST on QoL and reduced likelihood of hospitalization 
or death due to worsening HF.
Consistent with previous reports,35 over 40% of HF patients in our study sample had 
clinically significant depressive symptoms (BDI-II≥14). Of this subsample, those 
randomized to the CST intervention exhibited a marked and clinically-significant 8-point 
average reduction in BDI II score. These findings are consistent with those of a recent report 
showing cognitive behavior therapy to be an effective treatment for depression in HF 
patients with major depressive disorder.12 Unfortunately, evidence regarding the efficacy of 
antidepressants for treating depressive symptoms and improving outcomes in HF patients 
has been disappointing.36 We and others have previously shown that elevated depressive 
symptoms, and depressive symptoms that worsen over time regardless of initial severity, are 
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associated with adverse clinical outcomes in HF, independent of HF disease severity and 
comorbidity.5
For patients with chronic diseases, patient-centered outcomes and QoL are gaining 
widespread recognition as being important treatment targets for optimal patient 
management. QoL is a complex construct consisting of multiple health–related, and disease-
specific domains for which there are no universally accepted measures.37–39 Nonetheless, 
QoL measures have been shown to predict long term clinical outcomes and survival in 
cancer patients40 and in kidney transplant recipients.41 Several studies of HF patients also 
have linked QoL, measured by HF disease-specific health-related QoL self-report scales, to 
survival, but only one recently conducted secondary analysis of data from the COACH study 
demonstrated that this relationship remained robust after controlling for HF disease severity 
using HF biomarkers in hospitalized HF patients.4 Our study confirms and extends this 
finding by further demonstrating that QoL is an important and independent aspect of HF that 
is related to long-term clinical outcomes in HF outpatients who were on a stable medical 
regimen. Moreover, our results showed that an intervention designed to reduce psychological 
distress in HF patients can improve QoL and also help lower the risk of death or 
hospitalization due to worsening HF.
The present study was relatively small and the follow-up was for an average of only 3 years, 
limiting the power to detect differences in mortality and hospitalizations between treatment 
groups. Although our patients came from diverse clinical heart failure programs, they were 
recruited from only 3 sites, which may limit the generalizability of our findings. A further 
limitation is that participants in the CST condition had a similar number of phone calls, but 
sessions were longer compared with HFE. Although the duration of telephone intervention 
calls was unrelated to any outcome measure within each intervention group, the longer call 
duration for the CST condition cannot be ruled out as a potential confounding factor. It is of 
further note that a HF telemonitoring system that had previously demonstrated success in 
smaller scale trials, failed to scale successfully to a large-scale multi-site randomized 
controlled trial.42 Therefore, the present findings should be interpreted with caution; a larger 
scale trial spanning diverse clinical settings may be needed to establish the benefits and cost-
effectiveness of coping skills training for HF patients. Nonetheless, the COPE-HF trial 
findings are encouraging, and are supported by the inclusion of a HFE control group that not 
only controlled for patient contact and attention, but also provided equipoise in terms of 
anticipated outcome benefits to participants. It is also noteworthy that while the CST 
intervention was completed in 16 weekly phone calls, its benefits appeared to persist for 
years after its completion.
In summary, in a clinical efficacy trial, we found that a CST intervention delivered remotely 
by telephone showed promising results for improving overall QoL and reducing the risk of 
worsening HF hospitalizations and mortality in patients with HF. The present findings 
suggest that CST interventions also may be a feasible approach to reduce the burden on the 
health care system associated with managing this chronic disease. Our observations also 
underscore the importance of addressing the distress associated with living with HF, and 
providing patients with approaches and strategies to improve their ability to cope with their 
disease and reduce their distress. Remote interventions of this kind may increasingly play an 
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important role for patients with chronic debilitating diseases who may not have access to 
mental health facilities and may not be receptive to traditional mental health treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Clinical Perspective
Heart failure is a chronic, debilitating condition that requires comprehensive medical 
management by physicians, including pharmacologic and device therapies designed to 
limit and help reverse its severity. Unhealthy behaviors are often important etiologic 
factors in the development and progression of heart failure, and adoption of healthy 
lifestyle practices is therefore an important aspect of successful heart failure 
management. Findings from the present study confirm and extend growing evidence that 
implementing strategies designed to enhance patient self-management and improve 
coping may have beneficial effects on patient-centered outcomes. A novel finding from 
the study is that coping skills training delivered remotely by telephone improved quality 
of life more than health behavior education alone. These findings underscore the 
importance of addressing psychological distress associated with heart failure and 
providing patients with strategies to improve their ability to cope with their disease. 
Improving quality of life for heart failure patients also may help reduce the risk of 
hospitalizations or death due to worsening heart failure. Remote interventions of this kind 
could play an increasingly important role among heart failure patients, and may help 
reduce the systemic health care burden associated with managing this complex, chronic 
disease.
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Figure 1. 
CONSORT chart of trial enrollment.
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Figure 2. 
Adjusted Cox proportional hazards model comparing CST and HFE from randomization to 
3-year follow-up. CST participants exhibited a lower rate of HF hospitalizations and death 
(HR = 0.65 [0.44, 0.98], P=.040) after adjustment for age, ejection fraction, BNP, and 
hospitalizations in the year preceding randomization.
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Table 1
Background Characteristics of Study Sample. Values are presented as mean (SD) unless otherwise indicated.
Variable CST (n=89) HFE (n=90) Cohort (n=179) P-value
Age, years 57.6 (11.1) 57.9 (11.9) 57.7 (11.5) .90
Female, n (%) 27 (30%) 21 (23.3%) 48 (26.7%) .29
White, n (%) 50 (55.6%) 46 (51.1%) 96 (53.3%) .50
Ischemic etiology, n (%) 35 (38.9%) 37 (41.1%) 72 (40%) .81
Lab Results
Serum Creatinine, mg/dL 1.18 (0.37) 1.23 (0.42) 1.2 (0.40) .44
Hemoglobin, g/dL 13.5 (1.7) 13.4 (1.5) 13.4 (1.6) .66
Urinary Sodium, mg/24-hr 3550 (1734) 3882 (2055) 3717 (1903) .25
Dietary Sodium, mg/day 2993 (1461) 2806 (1653) 2899 (1559) .43
Medications
ACEI, n (%) 64 (72%) 69 (77%) 134 (74%) .47
ARB, n (%) 21 (23%) 16 (18%) 37 (21%) .34
Aldosterone Antagonists, n (%) 47 (52%) 47 (52%) 94 (52%) .99
Anticoagulants, n (%) 26 (29%) 27 (30%) 54 (30%) .91
Aspirin, n (%) 58 (64%) 60 (67%) 118 (65%) .83
Beta blocker, n (%) 87 (98%) 85 (94.4%) 173 (96%) .25
Antidepressant, n (%) 21 (23%) 33 (37%) 54 (30%) .06
Cholesterol drug, n (%) 62 (69%) 64 (71%) 126 (70%) .83
Diuretic, n (%) 78 (88%) 84 (93%) 163 (91%) .19
Nitrate, n (%) 21 (23%) 25 (28%) 46 (25%) .52
Medical History
Hypertension, n (%) 65 (73%) 67 (74%) 132 (74%) .83
Diabetes, n (%) 41 (46%) 49 (54%) 90 (50%) .26
Hyperlipidemia Dx, n (%) 57 (64%) 64 (71%) 122 (68%) .31
BiV Pacemaker, n (%) 32 (37%) 44 (49%) 77 (43%) .08
ICD, n (%) 63 (71%) 75 (83%) 139 (77%) .05
Quality of Life
BDI Score 14.2 ± 9.5 13.5 ± 10.4 13.9 ± 9.9 .64
AAI Score 47.3 (10.0) 48.0 (10.7) 47.6 (10.3) .66
STAI Score 28.1 (7.4) 31.3 (9.9) 29.7 (8.9) .03
KCCQ Score 58.1 (21.5) 55.6 (21.9) 56.8 (21.6) .43
6-min Walk Distance, meters 376 (98) 353 (114) 365 (107) .16
Heart Failure Disease Biomarkers
BNP, pg/ml 284.4 (485) 241.5 (318) 262.8 (409) .49
LVEF, % 31.7 (10.3) 28.4 (8.7) 30.0 (9.6) .02
HRV, SDNN 88.8 (28.1) 81.8 (29.2) 85.7 (28.7) .19
Flow Mediated Dilation, % 4.1 (4.1) 3.9 (4.2) 4.0 (4.2) .78
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Variable CST (n=89) HFE (n=90) Cohort (n=179) P-value
CRP, mg/L 3.7 (3.4) 4.0 (3.4) 3.8 (3.4) .57
ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; BiV=biventricular; ICD=implantable cardioverter 
defibrillator; BDI=Beck Depression Inventory; AAI=Attitudes About Impairment; STAI= State Anxiety; KCCQ=Kansas City Cardiomyopathy 
Questionnaire; BNP= B-Type Natriuretic Peptide; LVEF=left ventricular ejection fraction; HRV= Heart rate Variability; SDNN=standard deviation 
of normal to normal heartbeat intervals; CRP=C-reactive protein. Hypertension, diabetes or hyperlipidemia were defined as present if a diagnosis 
appeared in participants' medical records during the year preceding pre-randomization baseline assessments
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Table 2
Changes (mean change with confidence intervals) in Measures of Quality of Life (QoL) and Heart Failure 
Disease Biomarkers
Variable Coping Skills
Training
(n=89)
Heart Failure
Education
(n=90)
P-value
Quality of Life
Attitudes about Impairment 3.7 (2.2, 5.3) 1.8 (0.3, 3.2) .070
Beck Depression Inventory −4.5 (−5.8, −3.1) −2.4 (−3.7, −1.1) .027
KCCQ Total Score 8.3 (5.0, 11.5) 2.3 (−0.8, 5.4) .009
6-Min Walk Distance (meters) 15.8 (4.8, 26.7) −3.5 (−13.9, 7.0) .012
State Anxiety −2.6 (−4.4, −0.8) −0.2 (−1.9, 1.6) .057
Heart-Failure Disease Biomarkers
B-type Natriuretic Peptide (pg/ml) −23.5 (−63.6, 16.2) −25.0 (−62.9, 12.8) .958
Left Ventricular Ejection Fraction
(%)
0.2 (−0.9, 1.4) −1.3 (−2.4, −0.2) .066
Heart Rate Variability (SDNN) 2.0 (−4.7, 8.7) −3.7 (−11.0, 3.5) .246
Flow Mediated Dilation (%) 0.2 (−0.5, 0.9) 0.0 (−0.7, 0.7) .733
C-Reactive Protein (mg/L) −0.3 (−0.9, 0.2) 0.3 (−0.2, 0.9) .102
Values are adjusted for age, etiology of heart failure (ischemic vs. non-ischemic), and the pre-treatment level of the respective predictor. FMD 
analyses were also adjusted for baseline arterial diameter. KCCQ=Kansas City Cardiomyopathy Questionnaire; SDNN=standard deviation of 
normal to normal heartbeat intervals.
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Table 3
Treatment effects on all-cause hospitalization or death and Wei-Lin-Weissfeld integrated model of heart failure 
hospitalizations or death.
Variables All-cause Hospitalization
or Death
(127 events)
HF Hospitalization
or Death
(80 events)
Model
Hazard Ratio
(95% CI)
P-value Hazard Ratio
(95% CI)
P-value
Age (>60 vs. <60 yr) 1.07 (0.75, 1.54) .714 1.01 (0.67, 1.53) .949
Etiology (Ischemic vs. non-Ischemic) 1.00 (0.69, 1.43) .986 0.77 (0.48, 1.17) .203
BNP at baseline (1,000 pg/ml) 2.32 (1.58, 3.40) <.001 3.48 (2.31, 5.12) <.001
Ejection Fraction at baseline (10%) 1.00 (0.83, 1.21) .992 0.92 (0.75, 1.13) .437
Hospitalizations in Past Year (ref=0): 1–2
    ≥3
0.82 (0.55, 1.22)
1.77 (1.01, 3.07)
.337
.045
0.84 (0.52, 1.34)
1.77 (1.06, 2.97)
.462
.031
Coping Skills Training 0.84 (0.59, 1.21) .352 0.65 (0.44, 0.98) .040
Analyses of heart failure and death included 80 first events and 24 subsequent events (i.e. 24 individuals whose first event was a heart failure 
hospitalization subsequently died).
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